Literature DB >> 8548060

Effects of growth hormone overproduction on grip strength of transgenic mice.

E Wolf1, R Wanke, E Schenck, W Hermanns, G Brem.   

Abstract

Growth hormone (GH) is used by athletes like bodybuilders to increase muscle strength and weight gain. On the other hand, chronic hypersecretion of GH in active acromegaly may result in outwardly hypertrophied but functionally weaker muscles. As a model for studying long-term effects of GH on muscle strength, we analysed transgenic mice (TM) carrying rat phosphoenolpyruvate carboxykinase-bovine GH (PEPCKbGH) fusion genes, which are expressed in liver and kidney but not in skeletal muscle. Circulating GH levels in TM ranged between 0.5 and 3 micrograms/ml, resulting in increased (p < 0.001) body weight (wt) as well as increased (p < 0.01) weights of forelimb and hindlimb muscles. However, muscle weight/body wt ratios of TM were 16-20% smaller than in controls (p < 0.05). Forelimb grip strength of hemizygous TM (16 males, 132 +/- 45 days old, body wt = 56.8 +/- 8.3 g; 32 females, 146 +/- 38 days old, body wt = 54.9 +/- 6.1 g) and non-transgenic controls (28 males, 127 +/- 47 days old, body wt = 40.5 +/- 2.9 g; 33 females, 126 +/- 47 days old, body wt = 32.1 +/- 3.6 g) was determined using an automated grip strength meter. Data were computed by analysis of variance, taking into account effects of group, sex and age. Least-squares means estimated for the grip strength (N) of male TM (1.91) and controls (1.92) were significantly (p < 0.05) greater than those of female TM (1.78) and controls (1.61). A significant difference between groups was only seen in females (p < 0.01). Least-squares means estimated for grip strength/body wt ratios (N/10 g) of male (0.34) and female TM (0.33) were 29% and 35% lower than those of male (0.48) and female controls (0.51), respectively (p < 0.001). In summary, long-term elevated GH levels in TM increased muscle weight less efficiently than body weight, and muscle strength did not increase proportionally with muscle weight.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8548060     DOI: 10.1530/eje.0.1330735

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

1.  Actions and interactions of growth hormone and insulin-like growth factor-II: body and organ growth of transgenic mice.

Authors:  A Blackburn; A Schmitt; P Schmidt; R Wanke; W Hermanns; G Brem; E Wolf
Journal:  Transgenic Res       Date:  1997-05       Impact factor: 2.788

Review 2.  Claims for the anabolic effects of growth hormone: a case of the emperor's new clothes?

Authors:  M J Rennie
Journal:  Br J Sports Med       Date:  2003-04       Impact factor: 13.800

Review 3.  Musculoskeletal Effects of Altered GH Action.

Authors:  Jonathan A Young; Shouan Zhu; Edward O List; Silvana Duran-Ortiz; Yosri Slama; Darlene E Berryman
Journal:  Front Physiol       Date:  2022-05-19       Impact factor: 4.755

4.  A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis.

Authors:  Emmanuel Somm; Nicolas Bonnet; Alberto Martinez; Philip M H Marks; Verity A Cadd; Mark Elliott; Audrey Toulotte; Serge L Ferrari; René Rizzoli; Petra S Hüppi; Elaine Harper; Shlomo Melmed; Richard Jones; Michel L Aubert
Journal:  J Clin Invest       Date:  2012-08-01       Impact factor: 14.808

5.  Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.

Authors:  Angèle Nalbandian; Arif A Khan; Ruchi Srivastava; Katrina J Llewellyn; Baichang Tan; Nora Shukr; Yasmin Fazli; Virginia E Kimonis; Lbachir BenMohamed
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

6.  Growth hormone mediates pubertal skeletal development independent of hepatic IGF-1 production.

Authors:  Hayden-William Courtland; Hui Sun; Mordechay Beth-On; Yingjie Wu; Sebastien Elis; Clifford J Rosen; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2011-04       Impact factor: 6.741

7.  Mice overexpressing growth hormone exhibit increased skeletal muscle myostatin and MuRF1 with attenuation of muscle mass.

Authors:  Leslie A Consitt; Alicson Saneda; Gunjan Saxena; Edward O List; John J Kopchick
Journal:  Skelet Muscle       Date:  2017-09-04       Impact factor: 4.912

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.